Pharmaceuticals

Rising Prevalence Of Respiratory Disorders Driving Growth Of The Due To Air Pollution Is Supporting Expansion In The Live Attenuated Vaccines Market

May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Live Attenuated Vaccines Market Between 2026 And 2030?

The live attenuated vaccines market size has experienced significant growth in recent years. This market is anticipated to expand from $25.95 billion in 2025 to $28.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. The historical expansion can be attributed to factors such as the global infectious disease burden, government immunization initiatives, childhood vaccination policies, hospital-based vaccine delivery, and WHO vaccination programs.

The live attenuated vaccines market is poised for significant expansion in the coming years, with its size anticipated to reach $41.11 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.6%. This projected growth stems from several factors, including the rising demand for booster vaccinations, the risks posed by emerging infectious diseases, the expansion of cold chain infrastructure, increased global health funding, and the introduction of next-generation vaccine platforms. Notable trends expected during this period include the wider implementation of national immunization programs, an escalating demand for pediatric vaccinations, enhancements in vaccine stability and storage, a greater emphasis on pandemic preparedness, and the development of multivalent vaccines.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp

What Factors Are Contributing To The Growth Of The Live Attenuated Vaccines Market?

The expanding occurrence of infectious diseases is projected to drive the live attenuated vaccines market’s growth in the foreseeable future. These diseases are conditions resulting from detrimental microorganisms like bacteria, viruses, fungi, or parasites, which can be transmitted either directly or indirectly among individuals, animals, or from the environment. An increase in global travel intensifies the dissemination of infectious diseases, as it facilitates pathogens’ cross-border movement at a quicker rate than preventive measures can manage. Live attenuated vaccines are effective in preventing infectious diseases by eliciting a robust immune response through the use of attenuated pathogens, thereby providing enduring immunity and curtailing disease transmission. For example, the World Health Organization, an intergovernmental body based in Switzerland, reported in March 2025 that an estimated 10.8 million individuals contracted TB globally in 2023, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the heightened incidence of infectious diseases is fueling expansion in the live attenuated vaccines market.

Which Segment Classifications Are Used In The Live Attenuated Vaccines Market Segment Analysis?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

What Market Trends Are Affecting The Live Attenuated Vaccines Market?

Major companies operating within the live attenuated vaccines market are prioritizing the creation of advanced products, such as single-dose vaccines, to enhance immunization effectiveness and improve patient adherence. These single-dose vaccines provide enduring immunity from a solitary shot, thereby eliminating the requirement for multiple doses. This development simplifies vaccination procedures for both patients and healthcare providers, significantly enhancing convenience and accessibility. For instance, in November 2023, Valneva SE, a France-based biotech company that manufactures vaccines for infectious diseases, announced the introduction of IXCHIQ, which had received clearance from the U.S. Food and Drug Administration (FDA), a US-based health agency. IXCHIQ represents the world’s first live-attenuated chikungunya vaccine, specifically indicated for adults aged 18 and older. This approval is notably significant because IXCHIQ stands as the world’s first licensed vaccine for chikungunya, thereby fulfilling an unmet medical need for protection against this mosquito-borne viral disease, known for causing severe fever, joint and muscle pain, among other symptoms.

Which Firms Are Contributing To The Live Attenuated Vaccines Market Ecosystem?

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

Get The Full Live Attenuated Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

Which Region Is The Largest In The Live Attenuated Vaccines Market?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Live Attenuated Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

Browse Through More Reports Similar to the Global Live Attenuated Vaccines Market 2026, By The Business Research Company

Inactivated Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795